MCAS test: how mast cell activation is measured, and what the workup misses

Mast cells are immune cells that store chemical mediators, among them histamine and tryptase, and release them when activated. Mast cell activation syndrome (MCAS) describes episodes in which that release drives symptoms. A 2012 consensus proposal set out criteria for diagnosing mast cell activation and classified the syndromes as primary, secondary and idiopathic (Valent et al., 2012).

An MCAS test, in practice, is a set of measurements that look for a documented rise in a mediator during symptoms. A later critical review restates the criteria: typical symptoms in at least two organ systems; an event-related rise in serum tryptase above 120% of the person's baseline plus 2 ng/mL; and a response to drugs directed at mast cell mediators (JACI: In Practice, 2021). A clinician weighs all three.

Our piece on MCAS testing and what the standard workup misses goes through each step.

Mast cells sit in the skin, the gut lining, the airways and around blood vessels, and they release their mediators when activated (Valent et al., 2012). The mediators follow different clocks: after a systemic reaction, histamine in the blood peaked at 5 to 10 minutes, while tryptase peaked 1 to 2 hours after the trigger and stayed raised for several hours (Schwartz et al., 1989).

Our explainer on mast cells and cytokines covers how mast cells connect to the wider immune system. The symptoms of mast cell activation can span several organ systems, which is part of why the consensus criteria ask for at least two (JACI: In Practice, 2021).

People with long COVID or ME/CFS ask about MCAS because the symptom lists overlap in places. Our article on where MCAS symptoms overlap with long COVID and ME/CFS sets them side by side, and our guide to histamine intolerance and MCAS testing separates two conditions that people confuse. Neither overlap means one condition causes the other.

The standard workup has three parts (Valent et al., 2012). A baseline serum tryptase, drawn on a quiet day, sets your personal reference. A second tryptase, drawn during a flare or within hours of it, looks for the rise: from a baseline of 10 ng/mL, for example, the event level would need to reach 14 ng/mL (JACI: In Practice, 2021). Urine collections look for breakdown products of histamine and other mediators.

The weak point is timing. Tryptase peaks 1 to 2 hours after a reaction and falls over the following hours (Schwartz et al., 1989), so a draw the next day, or in a calm week, can read normal in someone who reacts. A urine collection has to capture a window that contains a flare. People cycle through repeat draws and hear that their results are fine while the episodes continue.

The workup measures mast cell mediators. It does not show what the rest of the immune system is doing between flares.

A flare diary helps whichever tests you have: the time each episode starts, what came before it, which organ systems were involved and how long it lasted. With that record, you and your doctor can plan an event draw inside the 1 to 2 hour window.

A broader panel reads tryptase beside the type-2 and alarmin cytokines of the allergic and barrier side of the immune system, such as IL-4, IL-5, IL-13, IL-33 and TSLP, and places each against a healthy reference. Measured at a baseline and at later dates, that gives you and your allergist or immunologist a wider picture of immune activity between flares.

A panel has firm limits here. It cannot diagnose MCAS, stand in for an event tryptase timed to a flare, or choose a treatment. A single draw can miss a flare. Mast cell mediators move within hours, so any result reflects the moment of the draw.

Mune Mirror™^* is currently in development, and the performance characteristics of this test have not yet been established. It is investigational. It does not diagnose, detect, screen for, treat, cure or prevent any disease. Results are for research and informational purposes, to discuss with your own doctor.

The guide to unwellness testing explains how this kind of measurement fits beside standard care.

Mune Mirror™ measures more than 1,000 immune and inflammation proteins from an at-home sample, including tryptase and the type-2 and alarmin cytokines in its Skin, Barrier and Allergy domain, and benchmarks each against a healthy reference. It adds immune context to the workup your allergist or immunologist runs. It does not diagnose MCAS and does not replace an event tryptase.

What blood test is used for MCAS?

Serum tryptase. Clinicians compare a tryptase drawn during symptoms, or within hours of them, with a baseline taken on a quiet day, and a rise above 120% of baseline plus 2 ng/mL supports the diagnosis alongside typical symptoms in two or more organ systems. Urine mediator tests can add evidence.

Why was my tryptase normal if I have mast cell symptoms?

Tryptase peaks 1 to 2 hours after a reaction and falls over the following hours, so a draw taken later, or on a calm day, can read normal. A normal baseline tryptase does not rule MCAS out, because the criteria look for a rise during an event. Ask your doctor about an event draw timed to a flare.

Do I need to be having symptoms for an MCAS test?

For the event tryptase, yes: a laboratory needs to draw the sample during a flare or within 1 to 2 hours of it, when tryptase peaks. The baseline tryptase comes from a quiet day. Your doctor arranges both.

Is there an at-home MCAS test?

No at-home test confirms MCAS. The event tryptase needs a laboratory draw timed to a flare. At-home immune panels can measure tryptase and related cytokines at the time of collection for context, and they do not diagnose MCAS.

Can a cytokine panel diagnose MCAS?

No. A cytokine panel shows where tryptase and immune signalling proteins sit against a healthy reference at the time of the draw. The diagnosis rests on consensus criteria that a clinician applies: typical symptoms, a documented mediator rise during an event and the response to treatment.